Odyssey Therapeutics Appoints CFO Jason Haas, Strengthening Ties with Ligand Pharmaceuticals

Odyssey Therapeutics Welcomes New CFO to Drive Financial Strategy

Odyssey Therapeutics, a clinical-stage biopharmaceutical company specializing in autoimmune and inflammatory diseases, appoints Jason Haas as its new chief financial officer (CFO). Mr. Haas brings a wealth of experience in investment banking and capital markets, which positions him to oversee the financial strategy and operations of Odyssey during a pivotal growth phase. His appointment is strategic, as the company aims to enhance its clinical and preclinical immunology portfolio. Gary D. Glick, founder and CEO of Odyssey Therapeutics, expresses optimism about Mr. Haas joining the team, citing his proven leadership in financial operations and his strategic insight as key assets for the company’s ambitious plans.

Before joining Odyssey, Mr. Haas served as CFO for Syros Pharmaceuticals, where he played a crucial role in strategic planning and fundraising efforts. His extensive career includes significant positions at major financial institutions such as Barclays, Deutsche Bank, and Goldman Sachs. Notably, he is also on the board of Ligand Pharmaceuticals, which enhances his relevance in the biopharmaceutical landscape. His educational credentials include a Bachelor of Arts in International Relations and Economics from Colgate University and an MBA in Finance from Columbia Business School. Mr. Haas emphasizes his commitment to advancing Odyssey's mission, which focuses on developing a robust pipeline of drug candidates aimed at achieving deep and durable remission for patients suffering from complex autoimmune and inflammatory conditions.

The appointment of Mr. Haas comes at a critical time for Odyssey Therapeutics, a company founded in 2021 that is dedicated to using innovative tools and a skilled team to create effective medicines. With the biopharmaceutical industry increasingly focused on addressing complex medical conditions, Odyssey's commitment to scientific advancement aligns with the growing demand for effective therapies in the autoimmune and inflammatory space. As Mr. Haas steps into his role, the company anticipates strengthening its position within the industry, leveraging his expertise to navigate financial challenges and capitalize on growth opportunities.

In addition to Mr. Haas's appointment, Odyssey Therapeutics continues to build momentum in its development pipeline, which is crucial for attracting potential investors and partners. The company’s focus on groundbreaking scientific advancements highlights its dedication to improving patient care in a market that requires innovative solutions. This strategic leadership change signifies a proactive step for Odyssey as it seeks to expand its influence and capabilities in the competitive biopharmaceutical sector.